References
- Draft Guidance for Industry: Assay development and validation for immunogenicity Testing of Therapeutic Protein Products. US Department of Health and Human Services, US FDA, Rockville, MD, USA (2016). www.fda.gov/downloads/Drugs/Guidances/UCM192750.pdf
- Guideline on Immunogenicity assessment of biotechnology-derived therapeutic proteins. European Medicines Agency, London, UK (2008). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003946.pdf
- Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. European Medicines Agency, London, UK (2012). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf
- Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. European Medicines Agency, London, UK (2012). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf
- Draft Guideline on Immunogenicity assessment of biotechnology-derived therapeutic proteins. European Medicines Agency, London, UK (2015). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/10/WC500194507.pdf
- EBF - Focus Workshop: Current analysis of immunogenicity – Best Practices and Regulatory Hurdles. http://focus201609.europeanbioanalysisforum.eu/slides-2/
- Iwamoto N , ShimadaT, UminoYet al. Selective detection of complementarity-determining regions of monoclonal antibody by limiting protease access to the substrate: nano-surface and molecular-orientation limited proteolysis. Analyst139 (3), 576–580 (2014).
- Iwamoto N , YamaneN, UminoYet al. The developmentof the validated LCMS bioanalysis of trastuzumab in human plasma using aselective detection method for complementarity-determining regions of monoclonal antibodies: nano-surface and molecular-orientation limited (nSMOL) proteolysis. Anal. Methods7, 9177–9183 (2015).
- Iwamoto N , TakahashiM, HamadaAet al. Multiplex LCMS bioanalysis of brentuximab vedotin rituximab and cetuximab towards therapeutic drug monitoring application by combined calibration curve using fab-Selectivelimited proteolysis nSMOL. Clin. Pharmacol. Biopharm. 5, 164 (2016).
- Nakamura K , Hirayama-KurogiM, ItoSet al. Large-scale multiplex absolute protein quantification of drug-metabolizing enzymes and transporters in human intestine, liver, and kidney microsomes by SWATH-MS: Comparison with MRM/SRM and HR-MRM/PRM. Proteomics16 (15–16), 2106–2117 (2016).
- Timmerman P , WhiteS, McDougallSet al. Tiered approach into practice: scientific validation for chromatography-based assays in early development – a recommendation from the European Bioanalysis Forum. Bioanalysis7 (18), 2387–2398 (2015).
- van de Merbel N , SavoieN, YadavMet al. Stability: Recommendation for best practices and harmonization from the Global Bioanalysis Consortium Harmonization Team. AAPS J. 16 (3), 392–399 (2014).
- Japan Bioanalysis Forum 8th JBF Symposium. http://bioanalysisforum.jp/en/8th_JBFsympo_info